Human DNA Vaccines Market Size & Share Analysis - Growth Trends and Forecast (2027 - 2032)

The Human DNA Vaccines Market is Segmented by Vaccine Purpose (Prophylactic DNA Vaccines, Therapeutic DNA Vaccines), Product Type (Plasmid DNA Vaccines, and More), Delivery Method (Electroporation, and More), Route of Administration (Intradermal, and More), Indication (Infectious Diseases, and More), End-User (Hospitals and Clinics, and More), and Geography (North America, Europe, and More). Market Forecasts in Value (USD).

Human DNA Vaccines Market Size and Share

Human DNA Vaccines Market Size
Image © Mordor Intelligence. Reuse requires attribution under CC BY 4.0.

Human DNA Vaccines Market Analysis by Mordor Intelligence

The Human DNA Vaccines Market size is projected to be USD 357.44 million in 2026, USD 384.43 million in 2027, and reach USD 553.18 million by 2032, growing at a CAGR of 7.55% from 2027 to 2032.

Growth is linked to late-stage oncology programs, demand for infectious-disease preparedness, and manufacturing methods that can shorten production cycles. The human DNA vaccines market also benefits from work on formulations that may reduce dose requirements and lessen reliance on conventional delivery devices. Developers are pursuing regulatory milestones in China and the United States, while manufacturers are expanding cell-free DNA capacity. These changes may widen the commercial role of the platform, although reimbursement precedent and device requirements remain important constraints. The human DNA vaccines market remains fragmented because antigen developers, delivery specialists, and manufacturers generally operate in separate parts of the value chain.

Key Report Takeaways

  • By vaccine purpose, prophylactic DNA vaccines held 52.42% of revenue in 2026, while therapeutic DNA vaccines are forecast to grow at an 8.12% CAGR through 2032.
  • By product type, plasmid DNA vaccines held 43.25% of revenue in 2026, and it is also projected to expand at a 9.15% CAGR through 2032.
  • By delivery method, electroporation held 38.21% of revenue in 2026, while lipid and nanoparticle delivery is forecast to grow at a 10.26% CAGR through 2032.
  • By route of administration, intradermal held 41.13% of revenue in 2026, while intramuscular is expected to grow at a 9.71% CAGR through 2032.
  • By indication, infectious diseases held 45.52% of revenue in 2026, while oncology is forecast to grow at a 10.71% CAGR through 2032.
  • By end-user, hospitals and clinics held 42.22% of revenue in 2026, while government and public-health suppliers are expected to grow at 8.64% CAGR through 2032.
  • By geography, North America held 47.36% of revenue in 2026, while Asia-Pacific is projected to grow at 11.37% CAGR through 2032.

Note: Market numbers in this report are based on Mordor Intelligence's proprietary estimation framework, which combines nine months of actuals with Q4 projections for base year 2026.

Human DNA Vaccines Market Segment Analysis

By Vaccine Purpose:

Prophylactic Programs Retain the Largest Base While Therapeutic Programs Grow Faster

Prophylactic DNA vaccines captured 52.42% of the human DNA vaccines market share in 2026. Their position reflected their use in infectious-disease prevention programs where storage flexibility and manufacturing options matter. Programs have included MERS, Lassa fever, Ebola, and HPV-related prevention. Therapeutic DNA vaccines are forecast to grow at an 8.12% CAGR from 2027 to 2032. The human DNA vaccines market size for therapeutic vaccines is supported by oncology and HPV-associated disease programs nearing regulatory decisions. The planned China submission for VGX-3100 follows the positive Phase 3 topline result reported in May 2026.

INO-3107 also gives the therapeutic category an important United States regulatory event in 2026. Prophylactic and therapeutic programs can use similar plasmid production infrastructure. Shared facilities may improve batch economics as clinical demand increases. This model may be useful when developers operate multiple programs from the same platform. The two categories, therefore, do not rely entirely on separate manufacturing systems. That connection allows manufacturing improvements to benefit both parts of the human DNA vaccines industry.

Need more granular breakdown of segment shares?

Get tailored market insights for your requirements.

Human DNA Vaccines Market Share by Vaccine Purpose, 2026
Image © Mordor Intelligence. Reuse requires attribution under CC BY 4.0.

By Product Type:

Plasmid DNA Holds the Largest Position as Alternative Formats Advance

Plasmid DNA vaccines held 43.25% of product-type revenue in 2026 and are also projected to expand at a 9.15% CAGR through 2032. This position was supported by accumulated production knowledge and established analytical practices. Plasmid formats also appear across a broad range of active clinical programs. CDMOs are increasing batch capacity as clinical supply needs rise. The human DNA vaccines market continued to rely on plasmids because their development path is familiar to many program sponsors.

Linear and minicircle formats are receiving more attention for their physical properties. A 2025 Scientific Reports study found that Ministring DNA showed greater resistance to chemical and mechanical stress than conventional plasmid DNA. The study also found that lyophilization extended the shelf life for the material assessed. Enzymatic DNA studies have shown comparable in vivo immune responses to plasmid material. These findings create pressure for product formats that can shorten manufacturing timelines. The human DNA vaccines market may therefore support several DNA formats rather than a single permanent standard.

By Delivery Method:

Electroporation Leads Current Use, While Lipid and Nanoparticle Delivery Grows Fastest

Electroporation held 38.21% of delivery-method revenue in 2026. It has remained important because it supports plasmid uptake across active Phase 2 and Phase 3 programs. Its clinical role has helped establish repeatable administration methods in specialist settings. Lipid and nanoparticle delivery is forecast to grow at 10.26% CAGR from 2027 to 2032. This rate reflects work to apply delivery approaches developed for mRNA products to DNA payloads. The human DNA vaccines market size for lipid and nanoparticle delivery is linked to the possibility of lowering effective dose thresholds.

A 2026 review identified stronger immune responses for nanoparticle-coated DNA than electroporation in selected direct comparisons. This evidence gives developers a reason to test delivery options beyond powered devices. Liposome and polymer systems also remain under investigation. Each alternative needs adequate clinical evidence and practical delivery performance. As that evidence develops, the human DNA vaccines market may experience a gradual shift in the delivery-method mix.

By Route of Administration:

Intradermal Delivery Holds the Largest Share, While Intramuscular Delivery Gains Pipeline Support

Intradermal delivery held 41.13% of the route of administration revenue in 2026. This position is linked to the electroporation approaches used in many established development programs. Intradermal delivery can support localized activation of antigen-presenting cells. Intramuscular delivery is expected to grow at 9.71% CAGR from 2027 to 2032. The human DNA vaccines market for intramuscular delivery is supported by DNA formulations designed for lipid nanoparticle depot delivery. The use of intramuscular injection as a familiar route for nucleic acid vaccine development also supports it.

The Phase 1b INO-4500 trial reported intramuscular electroporation tolerability in a diverse group of healthy adults. Subcutaneous delivery also received support from work on lyophilized solid-dose formulations. A 2025 study reported stability at 4°C to 42°C for 30 days without cold-chain support. The findings supported the experimental feasibility of thermostable subcutaneous delivery. Oral and mucosal routes remain at an early preclinical stage. Route selection in the human DNA vaccines market will continue to depend on immune response, formulation design, and practical administration needs.

By Indication:

Infectious Diseases Lead Revenue While Oncology Expands at the Highest Rate

Infectious diseases accounted for 45.52% of the indication-level revenue in 2026. Active work has addressed MERS, Lassa fever, Ebola, HIV, and HPV-related diseases. ZyCoV-D remains the only approved human DNA vaccine. Oncology is forecast to grow at 10.71% CAGR from 2027 to 2032. This is the highest rate among the indications listed for the human DNA vaccines market. The growth outlook reflects increasing late-stage activity in therapeutic cancer programs.

A Phase 1 glioblastoma study published in 2026 further examined tailored multivalent neoantigen DNA vaccination. These studies provide clinical evidence for individualized oncology approaches. Allergies and autoimmune conditions remain at an early stage. Their possible relevance is linked to immune tolerance mechanisms. Infectious disease and oncology will therefore continue to define the main indication profile of the human DNA vaccines market.

Segment this market the way your business does.

Get tailored market insights for your requirements.

Human DNA Vaccines Market Share by Indication, 2026
Image © Mordor Intelligence. Reuse requires attribution under CC BY 4.0.
Human DNA Vaccines Market Share by Indication, 2026

By End-User:

Hospitals and Clinics Lead Current Use, While Public Health Suppliers Grow Fastest

Hospitals and clinics held 42.22% of end-user revenue in 2026. This human DNA vaccines market share reflects the need for supervised administration when products use electroporation. These settings can support trained staff, specialized equipment, and follow-up care. Government and public-health suppliers are expected to grow at an 8.64% CAGR from 2027 to 2032. The human DNA vaccines market relies on these institutional buyers, where early-development products serve public-health needs.

Research institutes and academic medical centers also support demand through investigator-led studies. They are particularly relevant for personalized neoantigen research and academic partnerships. Manufacturing capability remains important because these programs need cGMP material for clinical work. Touchlight’s licensed cell-free production site shows the growing availability of specialized DNA supply capacity. As therapeutic products advance, hospital oncology networks and specialty pharmacy channels may take a larger role after 2028.

Geography Analysis

North America

North America held 47.36% of the human DNA vaccine market share in 2026. The region has a dense clinical pipeline, substantial institutional funding, and an advanced regulatory environment for DNA medicine programs. INO-3107 has an FDA action date of October 30, 2026. A favorable U.S. outcome would create a commercial reference point for other candidates. Canada and Mexico contribute through research procurement and clinical trial activity.

Europe

Europe held the second-largest geographic position. The United Kingdom, Germany, and France host a concentration of DNA vaccine clinical programs. European developers also work across different antigen and delivery platforms. Regulatory requirements across the United Kingdom and the European Union can add work for smaller companies seeking access to both areas.

Asia-Pacific, South America, and the Middle East, and Africa

Asia-Pacific is projected to grow at an 11.37% CAGR from 2027 to 2032. It is the fastest-growing region in the human DNA vaccines market. China is an important near-term approval setting after the VGX-3100 Phase 3 result. The World Health Organization reported that South-East Asia accounted for 34% of global tuberculosis cases in 2024, while the Western Pacific accounted for 27%. This burden supports continued government attention to infectious diseases. South America, the Middle East, and Africa remain smaller areas, where partnerships and health infrastructure investment are important demand factors.

Human DNA Vaccines Market Growth Rate by Region
Image © Mordor Intelligence. Reuse requires attribution under CC BY 4.0.

Competitive Landscape

Market Concentration

Human DNA Vaccines Market Concentration
Image © Mordor Intelligence. Reuse requires attribution under CC BY 4.0.

The human DNA vaccines market is fragmented, and no company has a dominant commercial position. Competition operates across antigen development, delivery technologies, and DNA manufacturing. These groups do not always compete directly because they occupy separate parts of the value chain. INOVIO holds an advanced clinical position through its FDA-reviewed INO-3107 application. The company also has positive Phase 3 topline data for VGX-3100 from China.

Touchlight has expanded its strategic role through licensed cell-free DNA manufacturing. Its MHRA license and 2025 capacity expansion provide developers with an alternative to conventional plasmid production. A 2025 enzymatic DNA study supports this direction by reporting immune responses comparable with plasmid material. A second strategic direction is the use of lipid and nanoparticle formulations. These formulations may lower dose requirements and reduce device dependence. A third direction is the development of personalized neoantigen vaccines for oncology programs.

Companies with only electroporation-based delivery systems face a practical challenge if alternatives show strong later-stage results. Purchasers may increasingly seek data across more than 1 delivery method. Manufacturing quality requirements remain central to partnerships and product development. Developers also need clinical and regulatory evidence before alternative formats can establish commercial positions. The human DNA vaccines industry, therefore, has room for specialists in antigen design, delivery, and manufacturing.

Human DNA Vaccines Industry Leaders

  1. INOVIO Pharmaceuticals, Inc.

  2. Zydus Lifesciences Limited

  3. Genexine, Inc.

  4. GC Biopharma Corp.

  5. Takis Biotech S.r.l.

  6. *Disclaimer: Major Players sorted in no particular order

Human DNA Vaccines Market Companies Covered in this Report

  • Aldevron LLC
  • Applied DNA Sciences, Inc.
  • Elegen Bio, Inc.
  • Entos Pharmaceuticals Inc.
  • GC Biopharma Corp.
  • Geneos Therapeutics, Inc.
  • Genexine, Inc.
  • GeoVax Labs, Inc.
  • Immuno Cure BioTech Limited
  • INOVIO Pharmaceuticals, Inc.
  • NEC
  • PharmaJet, Inc.
  • Scancell Holdings plc
  • Shenzhen Geno-Immune Medical Institute
  • Takara Bio
  • Takis Biotech S.r.l.
  • Touchlight Genetics Limited
  • VGXI, Inc.
  • Vical Incorporated
  • Zydus Lifesciences Limited

Recent Industry Developments in Human DNA Vaccines Market

  • August 2026: Genexine Life Sciences received a USPTO Notice of Allowance for its COVID-19 DNA vaccine platform technology, jointly filed with the Korea Disease Control and Prevention Agency, extending IP protection to the United States following a 2024 Korean patent grant (10-2709169).
  • May 2026: ApolloBio reported positive topline Phase 3 results for VGX-3100, INOVIO's HPV DNA immunotherapy for cervical dysplasia, meeting its predefined primary efficacy endpoint. ApolloBio plans a regulatory submission in China.

Table of Contents for Human DNA Vaccines Industry Report

1. Introduction

  • 1.1 Study Assumptions and Market Definition
  • 1.2 Scope of the Study

2. Research Methodology

3. Executive Summary

4. Market Landscape

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Rising Oncology DNA-Immunotherapy Pipelines
    • 4.2.2 Infectious Disease and Pandemic-Preparedness Demand
    • 4.2.3 Rapid, Scalable, and Potentially Thermostable Manufacturing
    • 4.2.4 Expansion of Personalized Neoantigen Vaccine Development
    • 4.2.5 Cell-Free DNA Manufacturing Enabling Faster Sequence-to-Clinic Cycles
    • 4.2.6 Tissue-Localized T-Cell Responses for Rare Anatomical Disease
  • 4.3 Market Restraints
    • 4.3.1 Lower Immunogenicity with Conventional Injection
    • 4.3.2 Electroporation Device Burden and Administration Complexity
    • 4.3.3 Limited Human Commercial and Reimbursement Precedent
    • 4.3.4 Regulatory Uncertainty and Lengthy Clinical Validation Requirements
  • 4.4 Supply Chain Analysis
  • 4.5 Regulatory Landscape
  • 4.6 Technological Outlook
  • 4.7 Porter's Five Forces Analysis
    • 4.7.1 Threat of New Entrants
    • 4.7.2 Bargaining Power of Suppliers
    • 4.7.3 Bargaining Power of Buyers
    • 4.7.4 Threat of Substitutes
    • 4.7.5 Competitive Rivalry

5. Market Size & Growth Forecasts (Value, USD)

  • 5.1 By Vaccine Purpose
    • 5.1.1 Prophylactic DNA Vaccines
    • 5.1.2 Therapeutic DNA Vaccines
  • 5.2 By Product Type
    • 5.2.1 Plasmid DNA Vaccines
    • 5.2.2 Linear DNA Vaccines
    • 5.2.3 Minicircle DNA Vaccines
    • 5.2.4 Other Product Types
  • 5.3 By Delivery Method
    • 5.3.1 Electroporation
    • 5.3.2 Needle-Free Injection
    • 5.3.3 Suction-Based Delivery
    • 5.3.4 Lipid and Nanoparticle Delivery
    • 5.3.5 Liposome and Polymer Delivery
    • 5.3.6 Other Delivery Methods
  • 5.4 By Route of Administration
    • 5.4.1 Intradermal
    • 5.4.2 Intramuscular
    • 5.4.3 Subcutaneous
    • 5.4.4 Oral and Mucosal
    • 5.4.5 Other Routes of Administration
  • 5.5 By Indication
    • 5.5.1 Infectious Diseases
    • 5.5.2 Oncology
    • 5.5.3 Allergies and Autoimmune Conditions
    • 5.5.4 Other Indications
  • 5.6 By End-User
    • 5.6.1 Hospitals and Clinics
    • 5.6.2 Government and Public-Health Suppliers
    • 5.6.3 Research Institutes and Academic Medical Centers
    • 5.6.4 Pharmaceutical and Biotechnology Companies
    • 5.6.5 Contract Research and Manufacturing Organizations
  • 5.7 By Geography
    • 5.7.1 North America
    • 5.7.1.1 United States
    • 5.7.1.2 Canada
    • 5.7.1.3 Mexico
    • 5.7.2 Europe
    • 5.7.2.1 Germany
    • 5.7.2.2 United Kingdom
    • 5.7.2.3 France
    • 5.7.2.4 Italy
    • 5.7.2.5 Spain
    • 5.7.2.6 Rest of Europe
    • 5.7.3 Asia-Pacific
    • 5.7.3.1 China
    • 5.7.3.2 Japan
    • 5.7.3.3 India
    • 5.7.3.4 Australia
    • 5.7.3.5 South Korea
    • 5.7.3.6 Rest of Asia-Pacific
    • 5.7.4 Middle East and Africa
    • 5.7.4.1 GCC
    • 5.7.4.2 South Africa
    • 5.7.4.3 Rest of Middle East and Africa
    • 5.7.5 South America
    • 5.7.5.1 Brazil
    • 5.7.5.2 Argentina
    • 5.7.5.3 Rest of South America

6. Competitive Landscape

  • 6.1 Market Concentration
  • 6.2 Market Share Analysis
  • 6.3 Company Profiles (includes Global level Overview, Market level overview, Core Segments, Financials as available, Strategic Information, Market Rank/Share for key companies, Products & Services, Recent Developments)
    • 6.3.1 Aldevron LLC
    • 6.3.2 Applied DNA Sciences, Inc.
    • 6.3.3 Elegen Bio, Inc.
    • 6.3.4 Entos Pharmaceuticals Inc.
    • 6.3.5 GC Biopharma Corp.
    • 6.3.6 Geneos Therapeutics, Inc.
    • 6.3.7 Genexine, Inc.
    • 6.3.8 GeoVax Labs, Inc.
    • 6.3.9 Immuno Cure BioTech Limited
    • 6.3.10 INOVIO Pharmaceuticals, Inc.
    • 6.3.11 NEC Corporation
    • 6.3.12 PharmaJet, Inc.
    • 6.3.13 Scancell Holdings plc
    • 6.3.14 Shenzhen Geno-Immune Medical Institute
    • 6.3.15 Takara Bio Inc.
    • 6.3.16 Takis Biotech S.r.l.
    • 6.3.17 Touchlight Genetics Limited
    • 6.3.18 VGXI, Inc.
    • 6.3.19 Vical Incorporated
    • 6.3.20 Zydus Lifesciences Limited

7. Market Opportunities & Future Outlook

  • 7.1 White-space & Unmet-need Assessment

Global Human DNA Vaccines Market Report Scope

According to the report’s scope, the human DNA vaccines market refers to the global industry segment focused on developing, manufacturing, and commercializing DNA-based vaccines specifically for human use. These vaccines employ engineered DNA plasmids to stimulate immune responses against infectious diseases and certain cancers.

The human DNA vaccines market is segmented into vaccine purpose, product type, delivery method, route of administration, indication, end-user, and geography. By vaccine purpose, the market is segmented into prophylactic DNA vaccines and therapeutic DNA vaccines. By product type, the market is segmented into plasmid DNA vaccines, linear DNA vaccines, minicircle DNA vaccines, and other product types. By delivery method, the market is segmented into electroporation, needle-free injection, suction-based delivery, lipid and nanoparticle delivery, liposome and polymer delivery, and other delivery methods. By route of administration, the market is segmented into intradermal, intramuscular, subcutaneous, oral and mucosal, and other routes of administration. By indication, the market is segmented into infectious diseases, oncology, allergies and autoimmune conditions, and other indications. By end-user, the market is segmented into hospitals and clinics, government and public-health suppliers, research institutes and academic medical centers, pharmaceutical and biotechnology companies, and contract research and manufacturing organizations. By geography, the market is segmented into North America, Europe, Asia-Pacific, the Middle East and Africa, and South America. The report also covers the estimated market sizes and trends for 17 countries across major regions globally. The report offers values (USD) for all the above segments.  

Segmentation Overview

By Vaccine Purpose
Human DNA Vaccines Market segmentation breakdown
Prophylactic DNA Vaccines
Therapeutic DNA Vaccines
By Product Type
Human DNA Vaccines Market segmentation breakdown
Plasmid DNA Vaccines
Linear DNA Vaccines
Minicircle DNA Vaccines
Other Product Types
By Delivery Method
Human DNA Vaccines Market segmentation breakdown
Electroporation
Needle-Free Injection
Suction-Based Delivery
Lipid and Nanoparticle Delivery
Liposome and Polymer Delivery
Other Delivery Methods
By Route of Administration
Human DNA Vaccines Market segmentation breakdown
Intradermal
Intramuscular
Subcutaneous
Oral and Mucosal
Other Routes of Administration
By Indication
Human DNA Vaccines Market segmentation breakdown
Infectious Diseases
Oncology
Allergies and Autoimmune Conditions
Other Indications
By End-User
Human DNA Vaccines Market segmentation breakdown
Hospitals and Clinics
Government and Public-Health Suppliers
Research Institutes and Academic Medical Centers
Pharmaceutical and Biotechnology Companies
Contract Research and Manufacturing Organizations
By Geography
Human DNA Vaccines Market segmentation breakdown
North America United States
Canada
Mexico
Europe Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-Pacific China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle East and Africa GCC
South Africa
Rest of Middle East and Africa
South America Brazil
Argentina
Rest of South America
Human DNA Vaccines Market segmentation breakdown
By Vaccine Purpose Prophylactic DNA Vaccines
Therapeutic DNA Vaccines
By Product Type Plasmid DNA Vaccines
Linear DNA Vaccines
Minicircle DNA Vaccines
Other Product Types
By Delivery Method Electroporation
Needle-Free Injection
Suction-Based Delivery
Lipid and Nanoparticle Delivery
Liposome and Polymer Delivery
Other Delivery Methods
By Route of Administration Intradermal
Intramuscular
Subcutaneous
Oral and Mucosal
Other Routes of Administration
By Indication Infectious Diseases
Oncology
Allergies and Autoimmune Conditions
Other Indications
By End-User Hospitals and Clinics
Government and Public-Health Suppliers
Research Institutes and Academic Medical Centers
Pharmaceutical and Biotechnology Companies
Contract Research and Manufacturing Organizations
By Geography North America United States
Canada
Mexico
Europe Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-Pacific China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle East and Africa GCC
South Africa
Rest of Middle East and Africa
South America Brazil
Argentina
Rest of South America

Key Questions Answered in the Report

What is the projected value of human DNA vaccines by 2032?

The human DNA vaccines market is forecasted to increase from USD 357.44 million in 2026 to USD 384.43 million in 2027, and to reach USD 553.18 million by 2032, rising at a 7.55% CAGR through 2032.

Which vaccine purpose currently generates the most revenue?

Prophylactic DNA vaccines led with 52.42% of revenue in 2026, while therapeutic vaccines are expected to grow faster at 8.12% CAGR.

Which delivery approach is growing fastest for human DNA vaccines?

Lipid and nanoparticle delivery is forecasted to expand at 10.26% CAGR through 2032, the fastest rate among delivery methods listed.

Which region is forecast to grow fastest through 2032?

Asia-Pacific is projected to grow at 11.37% CAGR from 2027 to 2032, the highest regional rate.

Page last updated on: